Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
Boundless Bio (NASDAQ: BOLD), a clinical-stage oncology company, reported its Q1 2025 financial results and business updates. The company ended Q1 with a strong cash position of $138.3 million, providing runway into 2027. Key highlights include:
The company anticipates initial proof-of-concept data from its BBI-355 Phase 1/2 POTENTIATE trial in oncogene-amplified cancers in H2 2025. Their novel Kinesin program is progressing, with development candidate nomination expected by mid-2025 and IND filing planned for H1 2026.
Financial results show R&D expenses of $12.1 million (down from $13.1M in Q1 2024), G&A expenses of $5.2 million (up from $3.8M), and a net loss of $15.8 million (compared to $15.4M). The company also presented promising preclinical data for BBI-825, showing potential in preventing resistance in colorectal cancer models when combined with RAS inhibitors.
Boundless Bio (NASDAQ: BOLD), un'azienda oncologica in fase clinica, ha comunicato i risultati finanziari del primo trimestre 2025 e aggiornamenti sulle attività. La società ha chiuso il trimestre con una solida posizione di cassa di 138,3 milioni di dollari, garantendo liquidità fino al 2027. I punti salienti includono:
La società prevede i primi dati di prova di concetto dallo studio di fase 1/2 POTENTIATE con BBI-355 in tumori con amplificazione oncogenica nella seconda metà del 2025. Il loro innovativo programma Kinesin sta progredendo, con la nomina del candidato allo sviluppo prevista entro metà 2025 e la presentazione dell’IND programmata per la prima metà del 2026.
I risultati finanziari mostrano spese in R&S di 12,1 milioni di dollari (in calo rispetto ai 13,1 milioni del primo trimestre 2024), spese amministrative di 5,2 milioni di dollari (in aumento rispetto ai 3,8 milioni), e una perdita netta di 15,8 milioni di dollari (contro i 15,4 milioni). La società ha inoltre presentato dati preclinici promettenti per BBI-825, che mostrano potenzialità nel prevenire la resistenza nei modelli di cancro del colon-retto in combinazione con inibitori di RAS.
Boundless Bio (NASDAQ: BOLD), una compañía oncológica en etapa clínica, informó sus resultados financieros del primer trimestre de 2025 y actualizaciones comerciales. La empresa cerró el primer trimestre con una sólida posición de efectivo de 138,3 millones de dólares, asegurando fondos hasta 2027. Los puntos clave incluyen:
La compañía anticipa datos iniciales de prueba de concepto del ensayo de fase 1/2 POTENTIATE con BBI-355 en cánceres con amplificación oncogénica para la segunda mitad de 2025. Su novedoso programa Kinesin avanza, con la nominación del candidato a desarrollo prevista para mediados de 2025 y la presentación del IND planeada para la primera mitad de 2026.
Los resultados financieros muestran gastos en I+D de 12,1 millones de dólares (una disminución desde 13,1 millones en el primer trimestre de 2024), gastos administrativos de 5,2 millones de dólares (un aumento desde 3,8 millones), y una pérdida neta de 15,8 millones de dólares (comparado con 15,4 millones). La compañía también presentó datos preclínicos prometedores para BBI-825, mostrando potencial para prevenir la resistencia en modelos de cáncer colorrectal cuando se combina con inhibidores de RAS.
Boundless Bio (NASDAQ: BOLD)는 임상 단계의 종양학 회사로서 2025년 1분기 재무 결과 및 사업 업데이트를 발표했습니다. 회사는 1분기를 1억 3,830만 달러의 강력한 현금 보유고로 마감하며 2027년까지의 운영 자금을 확보했습니다. 주요 내용은 다음과 같습니다:
회사는 2025년 하반기에 종양 유전자 증폭 암에서 진행 중인 BBI-355 1/2상 POTENTIATE 시험의 초기 개념 증명 데이터를 기대하고 있습니다. 또한 신규 Kinesin 프로그램이 진척 중이며, 2025년 중반까지 개발 후보 지정을, 2026년 상반기에 IND 신청을 계획하고 있습니다.
재무 결과로는 연구개발 비용이 1,210만 달러(2024년 1분기 1,310만 달러 대비 감소), 일반관리비는 520만 달러(3,800만 달러에서 증가), 순손실은 1,580만 달러(1,540만 달러 대비)로 나타났습니다. 또한 회사는 BBI-825의 전임상 데이터도 발표했으며, 이는 RAS 억제제와 병용 시 대장암 모델에서 내성 예방 가능성을 보여줍니다.
Boundless Bio (NASDAQ : BOLD), une entreprise oncologique en phase clinique, a publié ses résultats financiers du premier trimestre 2025 ainsi que des mises à jour commerciales. La société a terminé le premier trimestre avec une trésorerie solide de 138,3 millions de dollars, assurant un financement jusqu’en 2027. Les points clés incluent :
La société prévoit des données initiales de preuve de concept issues de son essai de phase 1/2 POTENTIATE avec BBI-355 dans les cancers à amplification d’oncogènes au second semestre 2025. Leur nouveau programme Kinesin progresse, avec la nomination du candidat au développement attendue pour mi-2025 et le dépôt de l’IND prévu pour le premier semestre 2026.
Les résultats financiers montrent des dépenses en R&D de 12,1 millions de dollars (en baisse par rapport à 13,1 M$ au T1 2024), des frais généraux et administratifs de 5,2 millions de dollars (en hausse par rapport à 3,8 M$), et une perte nette de 15,8 millions de dollars (contre 15,4 M$). La société a également présenté des données précliniques prometteuses pour BBI-825, démontrant un potentiel pour prévenir la résistance dans des modèles de cancer colorectal en association avec des inhibiteurs de RAS.
Boundless Bio (NASDAQ: BOLD), ein klinisch fortgeschrittenes Onkologieunternehmen, berichtete über seine Finanzergebnisse für das erste Quartal 2025 und Geschäftsupdates. Das Unternehmen schloss das erste Quartal mit einer starken Barreserve von 138,3 Millionen US-Dollar ab, was eine Finanzierung bis 2027 sichert. Wichtige Highlights sind:
Das Unternehmen erwartet erste Proof-of-Concept-Daten aus der BBI-355 Phase 1/2 POTENTIATE-Studie bei onkogen-amplifizierten Tumoren in der zweiten Hälfte 2025. Das neuartige Kinesin-Programm macht Fortschritte, mit der Nominierung des Entwicklungskandidaten bis Mitte 2025 und der geplanten IND-Einreichung im ersten Halbjahr 2026.
Die Finanzergebnisse zeigen F&E-Ausgaben von 12,1 Millionen US-Dollar (gegenüber 13,1 Mio. USD im Q1 2024), Verwaltungskosten von 5,2 Millionen US-Dollar (gegenüber 3,8 Mio. USD) und einen Nettoverlust von 15,8 Millionen US-Dollar (verglichen mit 15,4 Mio. USD). Das Unternehmen stellte zudem vielversprechende präklinische Daten für BBI-825 vor, die Potenzial zeigen, Resistenz in Darmkrebsmodellen in Kombination mit RAS-Inhibitoren zu verhindern.
- Strong cash position of $138.3M providing runway into 2027
- BBI-355 Phase 1/2 trial progressing with data expected in H2 2025
- Novel Kinesin program advancing with clear development timeline
- Promising preclinical data for BBI-825 showing potential in preventing cancer drug resistance
- R&D expenses decreased year-over-year from $13.1M to $12.1M
- Net loss increased to $15.8M from $15.4M year-over-year
- G&A expenses increased significantly to $5.2M from $3.8M year-over-year
Insights
Boundless Bio reported steady financial position with $138.3M cash runway into 2027 while advancing key clinical and preclinical oncology programs targeting extrachromosomal DNA.
Boundless Bio's Q1 2025 financial results reveal a strong cash position of
The company's lead program, BBI-355, a CHK1 inhibitor targeting replication stress in oncogene-amplified cancers, continues enrollment in its Phase 1/2 POTENTIATE trial with preliminary proof-of-concept data expected in H2 2025. This timeline aligns with previous guidance, indicating the clinical program is progressing as planned. Their novel Kinesin program, which targets ecDNA segregation and inheritance, is advancing toward development candidate nomination by mid-2025 with IND filing projected for H1 2026.
Notably, Boundless presented preclinical data at AACR showing their ribonucleotide reductase inhibitor BBI-825 may delay or prevent acquired resistance when combined with RAS-targeting inhibitors in colorectal cancer models. This suggests potential for combination strategies to overcome a major challenge in targeted cancer therapy.
Boundless Bio's unique focus on extrachromosomal DNA (ecDNA) biology represents a differentiated approach to targeting oncogene-amplified cancers, which have historically been difficult to treat effectively. Their pipeline strategy addresses multiple aspects of ecDNA biology through different mechanistic approaches, potentially creating multiple shots on goal in addressing these challenging cancers.
Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025
Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing in the first half of 2026
SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2025.
“Boundless remains committed to delivering new therapeutic options to patients with high unmet need oncogene amplified cancers,” said Zachary Hornby, President and CEO of Boundless Bio. “We look forward to providing a clinical data update on our BBI-355 program later this year. Additionally, we expect to nominate a development candidate for our novel Kinesin program by mid-year, with plans to submit an IND in the first half of 2026."
Research and Development Highlights and Upcoming Milestones
BBI-355, a novel, oral, potent CHK1 inhibitor designed to target replication stress in oncogene-amplified cancers
- Enrollment is ongoing in the Phase 1/2 POTENTIATE trial. Preliminary clinical proof-of-concept safety and antitumor activity data are expected in the second half of 2025.
Novel Kinesin program targeting ecDNA segregation and inheritance
- Boundless expects to nominate a development candidate for its preclinical program targeting a previously undrugged kinesin by mid-2025, with an investigational new drug (IND) submission planned for the first half of 2026.
Recent Data Presentations
- Preclinical data from studies conducted with Boundless’s ribonucleotide reductase (RNR) inhibitor, BBI-825, were presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting. These data suggest that the combination of BBI-825 with mutant-specific, pan, and multi-RAS targeting inhibitors delayed or prevented acquired resistance in colorectal cancer preclinical models. Boundless continues to preclinically evaluate BBI-825 in various treatment settings.
First Quarter 2025 Financial Results
- Cash Position: Cash, cash equivalents, and short-term investments totaled
$138.3 million as of March 31, 2025. - Research and Development (R&D) Expenses: R&D expenses were
$12.1 million for the first quarter of 2025, compared to$13.1 million for the same period in 2024. - General and Administrative (G&A) Expenses: G&A expenses were
$5.2 million for the first quarter of 2025, compared to$3.8 million for the same period in 2024. - Net Loss: Net loss totaled
$15.8 million for the first quarter of 2025, compared to$15.4 for the same period in 2024.
About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors. Boundless’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14 to
Forward-Looking Statements
Boundless Bio cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include but are not limited to: the timing of expected preliminary clinical proof-of-concept data from the Phase 1/2 POTENTIATE trial, nomination of an ecDTx from the Kinesin program and submission of an IND application to the U.S. Food and Drug Administration (FDA) for that ecDTx, our anticipated cash runway and the sufficiency of our cash position to fund achievement of program milestones; the potential therapeutic applications and benefits of our ecDTx in treating patients with oncogene amplified cancers; our clinical and preclinical research and development plans for our ecDTx; and our ability to discover and develop new ecDTx. Our actual results and performance may differ materially from those expressed or implied in any forward-looking statement set forth in this press release due to numerous known and unknown risks and uncertainties, including, without limitation: we are early in our development efforts and our approach to discover and develop ecDTx directed against ecDNA in oncogene amplified cancers is novel and unproven; risks inherent in the business of discovering, developing, obtaining regulatory approval for, and commercializing drugs for use as human therapeutics and operating as an early clinical-stage company; we only have one ecDTx in clinical development and all of our other development efforts are in the discovery and preclinical development stage; results from preclinical studies or early clinical trials not necessarily being predictive of future results; potential delays in the commencement, enrollment, data readouts or completion of clinical trials or preclinical studies, or submission of an IND; final data from our clinical trials may be materially different from interim, topline or preliminary data we publish as more patient data become available and/or data undergo more comprehensive reviews and audit and verification procedures; analytical validation of our ecDNA diagnostic not necessarily being predictive of its clinical validity and utility; our dependence on third parties in connection with clinical trials, preclinical studies, ecDNA diagnostic development, and manufacturing; unfavorable results from clinical trials or preclinical studies; we may expend our limited resources to pursue a particular ecDTx and fail to capitalize on ecDTx with greater development or commercial potential; unexpected adverse side effects or inadequate efficacy of our ecDTx that may limit their development, regulatory approval, and/or commercialization; the potential for our programs and prospects to be negatively impacted by developments relating to our competitors, including the results of studies or regulatory determinations relating to our competitors; regulatory developments in the United States and foreign countries; disruptions in the FDA’s ability to perform routine activities or function in the normal course, including due to reduced staffing or funding levels, could result in longer review periods for our regulatory submissions and delay advancement of our ecDTx; we may use our capital resources sooner than we expect; we may be unable to obtain necessary additional funding when needed or on acceptable terms; the effect of macroeconomic and geopolitical events and conditions our business, operating costs, ability to raise additional capital, and stock price; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2024 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Contacts:
Ben Flaum, Boundless Bio
bflaum@boundlessbio.com
Renee Leck, THRUST Strategic Communications
renee@thrustsc.com
Media Contact:
Carly Scaduto
carly@carlyscadutoconsulting.com
| BOUNDLESS BIO, INC. | |||||||
| Financial Information | |||||||
| Statements of Operations Data: | Three Months Ended March 31, | ||||||
| (In thousands, except per share amounts) | 2025 | 2024 | |||||
| Operating expenses: | |||||||
| Research and development | $ | 12,138 | $ | 13,129 | |||
| General and administrative | 5,203 | 3,754 | |||||
| Total operating expenses | 17,341 | 16,883 | |||||
| Loss from operations | (17,341 | ) | (16,883 | ) | |||
| Other income, net: | |||||||
| Interest income | 1,585 | 1,421 | |||||
| Other income/ (loss), net | (2 | ) | 32 | ||||
| Total other income, net | 1,583 | 1,453 | |||||
| Net loss | $ | (15,758 | ) | $ | (15,430 | ) | |
| Net loss per share, basic and diluted | $ | (0.71 | ) | $ | (12.27 | ) | |
| Weighted-average shares used in calculation | 22,300 | 1,258 | |||||
| Balance Sheet Data: | March 31, | December 31, | |||||
| (In thousands) | 2025 | 2024 | |||||
| Cash, cash equivalents, and short-term investments | $ | 138,253 | $ | 152,114 | |||
| Total assets | $ | 191,242 | $ | 206,409 | |||
| Total liabilities | $ | 54,650 | $ | 55,767 | |||
| Accumulated deficit | $ | (217,230 | ) | $ | (201,472 | ) | |
| Total stockholders' equity | $ | 136,592 | $ | 150,642 | |||
| Working capital (1) | $ | 134,026 | $ | 146,255 | |||
| __________ | |||||||
| (1) We define working capital as current assets less current liabilities. | |||||||
FAQ
What is Boundless Bio's (BOLD) cash runway as of Q1 2025?
When will Boundless Bio (BOLD) release data from the BBI-355 POTENTIATE trial?
What was Boundless Bio's (BOLD) net loss in Q1 2025?
What are the key milestones for Boundless Bio's (BOLD) Kinesin program?
What were the findings from Boundless Bio's BBI-825 preclinical studies?
